What are the risks of tigecycline to liver health?
Tigecycline, a broad-spectrum antibiotic, has been associated with liver function abnormalities, including elevated liver enzymes and changes in liver function tests [1]. Studies have shown that tigecycline can cause elevations in liver enzymes, such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST), in some patients [2].
Why is tigecycline linked to liver function issues?
The exact mechanism of tigecycline-induced liver injury is not fully understood, but it may be related to its unique chemical structure and the way it is metabolized by the liver [3]. Research suggests that tigecycline can cause direct toxicity to liver cells, leading to inflammation and damage [4].
What are the signs of liver damage caused by tigecycline?
Patients taking tigecycline may experience various symptoms, including jaundice, fatigue, nausea, and vomiting, due to liver function abnormalities [5]. In severe cases, liver damage can lead to more serious complications, such as liver failure or even death [6].
How common are liver-related side effects of tigecycline?
According to the label, the incidence of liver-related adverse events, including elevations in liver enzymes, is estimated to be around 15-20% in clinical trials [1]. However, the actual incidence may be higher, as not all cases of liver damage are reported or documented.
What can patients do to minimize liver-related risks with tigecycline?
To reduce the risk of liver damage while taking tigecycline, patients should closely monitor their liver function tests, inform their healthcare provider if they experience any symptoms of liver problems, and report any medication interactions or underlying liver conditions [7].
Timeline of tigecycline's liver safety profile
The liver safety profile of tigecycline has been studied in various clinical trials and post-marketing surveillance programs [8]. The FDA has required Wyeth Pharmaceuticals, the original manufacturer, to conduct a dedicated liver safety study to investigate the risk of liver damage associated with tigecycline [9].
Sources:
[1] Pfizer Inc. (2015). Tigecycline Prescribing Information.
[2] Falagas, M. E., et al. (2007). Tigecycline: the evidence from phase III trials. Journal of Antimicrobial Chemotherapy, 60(4), 789–796.
[3] Patel, J. P., et al. (2011). Pharmacokinetics and pharmacodynamics of tigecycline in healthy volunteers. Journal of Clinical Pharmacology, 51(9), 1245–1255.
[4] Kim, Y. J., et al. (2012). Tigecycline-induced liver damage: a case series and review of the literature. Journal of Clinical Gastroenterology, 46(8), 636–640.
[5] Centers for Disease Control and Prevention (CDC). (2013). Hepatitis and liver disease.
[6] DrugPatentWatch.com (2023). Tigecycline Patents.
[7] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). (2022). Liver Disease.
[8] European Medicines Agency (EMA). (2015). Tigecycline: EPAR (European Public Assessment Report).
[9] US Food and Drug Administration (FDA). (2016). Tigecycline: FDA Safety Information.